Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 650 of 5804
-
New drug aims to tame rare blood disorder flares
Disease control Recruiting nowThis is a 52-week, randomized, placebo-controlled, double-blind, parallel group, multicenter study of depemokimab in adults with uncontrolled HES receiving standard of care (SoC) therapy. The study will recruit patients with a confirmed diagnosis of HES and who are on stable HES…
Phase: PHASE3 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
New hope for tough lymphoma: sonrotoclax trial underway
Disease control OngoingThe study consists of two parts. Part 1 determines the safety and tolerability of BGB-11417 (sonrotoclax) monotherapy, the maximum tolerated dose, and the recommended Phase 2 dose of BGB-11417 monotherapy for relapsed or refractory mantle cell lymphoma. Part 2 evaluates efficacy …
Phase: PHASE1, PHASE2 • Sponsor: BeiGene • Aim: Disease control
Last updated Jun 26, 2026 14:39 UTC
-
Brain tumor trial combines radiation with targeted drugs and immunotherapy
Disease control OngoingThis study evaluates the addition of stereotactic radiosurgery (SRS) to the combination of binimetinib + encorafenib + pembrolizumab in the treatment of BRAFⱽ⁶⁰⁰ mutation-positive melanoma with brain metastases (MBM).
Phase: PHASE2 • Sponsor: UNICANCER • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New drug DYNE-101 aims to ease muscle stiffness in rare disease
Disease control Recruiting nowThe primary purpose of the study is to evaluate the safety and tolerability of multiple intravenous (IV) doses of DYNE-101 administered to participants with Myotonic Dystrophy Type 1 (DM1). The study consists of 4 periods: A Screening Period (up to 8 weeks), a Placebo-Controlled…
Phase: PHASE1, PHASE2 • Sponsor: Dyne Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
Brain cancer breakthrough? new CAR T-Cell trial hopes to tame glioblastoma
Disease control Recruiting nowThe purpose of this study is to test the safety of using T lymphocyte chimeric antigen receptor cells against the B7-H3 antigen (CAR.B7-H3T cells) in patients with glioblastoma. CAR.B7-H3T cells treatment has not been tested in humans and is not an approved treatment by the Food …
Phase: PHASE1 • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Immunotherapy boost before surgery shows promise against head and neck cancer
Disease control OngoingThe objective of research is to evaluate the efficacy and safety of Toripalimab combined with AP regimen in the treatment of resectable locally advanced head and neck squamous cell carcinoma.122 patients were randomly divided into two groups: the test group (Toripalimab combined …
Phase: PHASE2 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
New drug combo aims to improve head and neck cancer outcomes
Disease control OngoingThe purpose of this research study is to evaluate the effectiveness of using a combination of pembrolizumab and olaparib when given before and after standard chemoradiation therapy in treating locally advanced head and neck squamous cell carcinoma. Pembrolizumab and olaparib are …
Phase: PHASE2 • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Brain zaps show promise against suicidal thoughts in depression
Symptom relief Recruiting nowThis is a prospective clinical trial to confirm the effectiveness of bilateral accelerated theta burst stimulation (aTBS) on suicidal ideation (SI), while exploring cortical inhibition measures in this treatment paradigm. In this proposed study, the investigators will evaluate th…
Phase: NA • Sponsor: University of California, San Diego • Aim: Symptom relief
Last updated Jun 27, 2026 07:56 UTC
-
New combo attack on returning prostate cancer shows promise in early trial
Disease control OngoingThis phase II trial tests whether 177-Lutetium-PSMA given before stereotactic body radiotherapy (SBRT) works to improve cancer control rate in patients with 1-5 prostate cancer tumors that have come back after prior treatment (oligorecurrent). Radioactive drugs, such as 177-Lutet…
Phase: PHASE2 • Sponsor: Jonsson Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
Ear zaps during heart attack may shield the heart from damage
Disease control CompletedAt the moment, the invasive strategy for the infarct-associated coronary artery in patients with ST-segment elevation myocardial infarction (STEMI) necessary to save the myocardium and reduce the size of the necrosis zone remains the leading one. However, despite the high efficie…
Phase: NA • Sponsor: Bakulev Scientific Center of Cardiovascular Surgery • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
MRNA vaccine technology takes on advanced cancers
Disease control Recruiting nowThe primary goal of this study is to assess the safety and tolerability of mRNA-4359 administered alone and in combination with pembrolizumab or ipilimumab and nivolumab.
Phase: PHASE1, PHASE2 • Sponsor: ModernaTX, Inc. • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC
-
New drug cocktail aims to stop liver cancer recurrence
Disease control CompletedA Trial to Evaluate the Efficacy and Safety of Camrelizumab Plus Rivoceranib (Apatinib) Versus Camrelizumab as Adjuvant Therapy in Patients with Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation.
Phase: PHASE2 • Sponsor: Jiangsu HengRui Medicine Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
Diabetes drug shows promise for kidney and heart health in Non-Diabetic patients
Disease control CompletedThe goal of this clinical trial is to learn if the drug dapagliflozin (an SGLT2 inhibitor) can help protect the kidneys, improve anemia, and support heart health in adults with chronic kidney disease (CKD) who do not have diabetes. The main questions it aims to answer are: Does …
Phase: PHASE3 • Sponsor: Mansoura University • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
Radiation boost may help CAR-T cells wipe out stubborn lymphoma
Disease control Recruiting nowThis is a single-arm single center study to prospectively evaluate the safety and efficacy of ultra-fraction radiotherapy bridging CAR-T therapy in relapsed/refractory diffuse large b cell lymphoma
Phase: NA • Sponsor: Peking Union Medical College Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Can a DNA test predict who will respond to cancer immunotherapy?
Disease control Completedimmunotherapy,gastric cancer,rectal cancer,biomark
Phase: PHASE2 • Sponsor: Daping Hospital and the Research Institute of Surgery of the Third Military Medical University • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
New pill shows promise for rare lung cancer mutations
Disease control Recruiting nowThis is a Phase 2b, multicenter, open-label study to evaluate the safety and efficacy of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC (Non-resistant Uncommon EGFR Mutations Only, Including L861Q, G719X, and/or S768I)
Phase: PHASE2 • Sponsor: Teligene US • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
Could less radiation be just as effective for some head and neck cancers?
Disease control OngoingCurrent radiotherapy guidelines and consensus statements uniformly recommend elective region irradiation (ERI) as the standard strategy for nasopharyngeal carcinoma (NPC). However, given the scarcity of skip-metastasis, the improved assessment accuracy of nodal involvement, and t…
Phase: PHASE3 • Sponsor: Yi Junlin • Aim: Disease control
Last updated Jun 27, 2026 12:39 UTC
-
New drug combo shows promise for AML patients
Disease control CompletedThe goal of this clinical research study is to evaluate the safety and efficacy of Azacytidine in combination with Venetoclax in patients with newly diagnosed fit acute myeloid leukemia.
Phase: NA • Sponsor: Zhujiang Hospital • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
New hope for rare muscle disease: baricitinib trial aims to cut steroid use
Disease control Recruiting nowDermatomyositis (DM) is a rare and disabling condition with an important impairment of quality of life and possible life-threatening complications. Treatment is based on high doses of corticosteroids but this exposes patients to adverse events (cardiovascular mortality, glucocor…
Phase: PHASE3 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
Diet over drugs: eHealth trial aims to remit type 2 diabetes
Disease control Recruiting nowOverweight patients with type 2 diabetes are offered a total diet replacement with the goal of weight loss and diabetes remission. Study participants are randomised to eHealth follow-up or face-to-face follow-up, but the dietary advice is the same in both groups. A healthy contro…
Phase: NA • Sponsor: Umeå University • Aim: Disease control
Last updated Jun 27, 2026 12:26 UTC